Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial - Cramer, Paula; Fürstenau, Moritz; Robrecht, Sandra; Giza, Adam; Zhang, Can; Fink, Anna-Maria; Fischer, Kirsten; Langerbeins, Petra; Al-Sawaf, Othman; Tausch, Eugen; Schneider, Christof; Schetelig, Johannes; et al. (The lancet. Haematology, 2022)
Gesehen am 23.01.2023